Advanced Liver Cancer Patients Live Longer By Taking Anti-cancer Drug Sorafenib

Researchers have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug. The findings are a significant advance in the management of liver cancer, which is the third cause of cancer death globally, often resulting in death within a year of diagnosis.

Read the whole article on Science Daily

More from Science Daily